We were delighted to speak with our Expert Faculty member, Prof. Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal), about the need to look for comorbidities in psoriasis.
His talk entitled ‘Is there a need to look for comorbidities in psoriasis?’ was presented at the EADV Spring Symposium, 6-7 May 2021.
- What cardiometabolic comorbidities are associated with psoriasis and why are these underdiagnosed and undertreated? (0:18)
- How do these comorbidities impact the treatment choices for our patients with psoriasis? (1:19)
- How can we improve the global management of patients with psoriasis and what are the benefits of such management? (1:58)
- What were the key take-home messages of the session? (2:49)
Disclosures: Tiago Torres has acted as a consultant, advisor, or speaker for Abbvie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers-Squibb, Celgene, Janssen, LEO Pharma, Eli-Lilly, MSD, Mylan, Novartis, Pfizer, Sandoz, Samsung-Bioepis, UCB and Viatris.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring Symposium 2021 (Virtual).
Share this Video
Related Videos In Psoriasis
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Linda Stein Gold, EADV 2022: Quality of Life and Clinical Efficacy Findings from PSOARING 1 and PSOARING 2
PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) were two phase 3 trials investigating tapinarof cream, a novel, steroid-free, AhR modulating agent for the treatment of plaque psoriasis. It was a pleasure to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) around the aims, design, endpoints and quality of life and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!